enGene Therapeutics Inc. Warrants financials
$0.2201−35.26%
Close Sep 25, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Oct 31 | FY24 Oct 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$123.2M | -$62.3M |
| Net income | -$117.3M | -$55.1M |
| Net margin | — | — |
| Diluted EPS | $-2.29 | $-1.46 |
| EBITDA | -$122.7M | -$62.0M |
| Operating cash flow | -$99.2M | -$48.3M |
| Free cash flow | -$100.7M | -$49.2M |
| Diluted shares | 51.1M | 37.8M |
Balance sheet
| Period end | Oct 31 | Oct 31 |
|---|---|---|
| Cash & equivalents | $50.2M | $173.0M |
| Short-term investments | $143.6M | $65.3M |
| Total debt | $23.3M | $23.2M |
| Total assets | $221.5M | $311.2M |
| Total liabilities | $53.8M | $38.6M |
| Shareholders' equity | $167.7M | $272.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology